NDAORALTABLETPriority Review
Approved
Jul 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
LYSODREN (mitotane) by Esteve is cytochrome p450 3a4 inducers [moa]. First approved in 1970.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYSODREN (mitotane) is an oral tablet that acts as a cytochrome P450 3A4 inducer, fundamentally altering drug metabolism in the body. It is indicated for adrenocortical carcinoma and has been approved since 1970. The mechanism involves potent enzyme induction that increases hepatic clearance of numerous medications and endogenous compounds.
$0.002BPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D spending ($2M in 2023) and minimal promotional runway, indicating small, maintenance-focused teams.
Mechanism of Action
Cytochrome P450 3A4 Inducers
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LYSODREN currently has zero linked job openings and minimal active career opportunities, reflecting its niche positioning and approaching loss of exclusivity. Career roles on this product are likely limited to maintenance-level commercial and medical affairs support within Esteve's rare disease/oncology franchise.
Worked on LYSODREN at Esteve? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.